The Duke Precision Medicine Program aims to bring proven precision medicine technologies from the basic science portfolio to the clinical settings through both research and clinical programs. Precision medicine technologies are broad-based and include specific tools such as wearables or our family history risk assessment platform, as well as predictive models that incorporate multiple modalities using state of the art scientific principles like machine learning. Housed in the Division of General Internal Medicine in the Duke Department of Medicine, our team is particularly interested in incorporating 'omic technologies, such as genomics, transcriptomics, and epigenomics, into clinical environments to enhance patient care and has broad based expertise in health services research, implementation science, and complex data. 

"Precision Medicine is the future of medicine and we are excited to be on the forefront of research, advancements, and discoveries." - Lori Orlando, Director of the Duke Precision Medicine Program

Lori Orlando

Lori Orlando, MD, MHS, MMCI
Director of the Duke Precision Medicine Program

Learn more about our work

The pace of precision medicine is rapidly accelerating and it’s potential to improve individual and population health is as well. However, precision medicine’s unique complexities make it difficult to incorporate into our existing healthcare infrastructure and processes.

Our goal is to identify and address these challenges so that patients and providers have the data, tools, and resources they need to optimize health.

Research

Our team is dedicated to advancing research in precision medicine through ongoing studies through trial networks housed at Duke University.

  • GUARDD-US: Genetic testing to understand renal disease disparities across the US through the IGNITE Pragmatic Clinical Trials Network

Health Care

Our team has developed and implemented various initiatives, programs, and tools, to bring precision medicine into the hands of providers, including both clinicians and pharmacists.

  • PHASER: Pharmacogenomics Testing for Veterans program (PHASER), brings pharmacogenomic testing to Veterans across the country receiving care at a VA. Led by Founding Director, Deepak Voora, PHASER uses this type of testing to optimize prescriptions using genetic data from patients to reduce adverse side effects and improve medication outcomes. 
  • MeTree: Developed by the Duke Precision Medicine Program, MeTree is a web-based, patient-facing risk assessment tool that collects personal health information and family health history.

Education & Training

Educating the next generation of researchers and health care providers in genomics and precision medicine is part of the fabric of our values. We are committed to providing extraordinary mentorship and educational experiences to future genomics researchers, educators, and clinicians.

News & Recognition

See what's happening at the Duke Precision Medicine Program:


Haga authors "The Book of Genes and Genomes"

Susanne B. Haga, PhD, associate professor of medicine and co-director of educational programs at the Duke Center for Applied Genomics & Precision Medicine has authored a new book, "The Book of Genes and Genomes" providing readers an easy to understand overview of the advances in genetics and genomics.

Early exercise interventions used from Duke trial to decrease cardiovascular disease

With 2022 underway and we are still living a relentless pandemic, our health continues to be of the upmost importance and physical activity has been shown to not only improve health, but help prevent the onset of many diseases. In February we celebrate and raise awareness for Heart Month, a time when the national spotlight is on cardiovascular disease. One cardiologist at Duke focused on heart disease, specifically from a preventative standpoint, is Dr. William E. Kraus.

CAGPM’s MeTree software recommended by President’s Cancer Panel

More effective and equitable implementation of cancer screening represents a significant opportunity for the National Cancer Program, with the potential to reduce the burden of cancer, according to a report released February 2, 2022, by the President’s Cancer Panel. The Panel’s report, Closing Gaps in Cancer Screening: Connecting People, Communities, and Systems to Improve Equity and Access, presents goals and recommendations to optimize cancer screening informed by a series of meetings conducted 2020-2021.

Woods publishes "At-home testing to mitigate community transmission of SARS-CoV-2"

The Duke Center for Applied Genomics & Precision Medicine’s Associate Director, Christopher W. Woods, MD, co-authored a recent publication in the BMC Public Health Journal studying the impact of rapid at-home testing on COVID-19 trends, “At-home testing to mitigate community transmission of SARS-CoV-2: protocol for public health intervention with a nested prospective cohort study.” This non-pharmaceutical intervention remains critical to controlling disease transmission and can ease the burden associated with facility-based testing. At-home testing can additionally improve testing access in high-risk communities. This study evaluates the impact that at-home testing has on both COVID-19 transmissions and socio-behavioral patterns in underserved populations.

Surprise! The Pandemic Has Made People More Science Literate

More effective and equitable implementation of cancer screening represents a significant opportunity for the National Cancer Program, with the potential to reduce the burden of cancer, according to a report released February 2, 2022, by the President’s Cancer Panel. The Panel’s report, Closing Gaps in Cancer Screening: Connecting People, Communities, and Systems to Improve Equity and Access, presents goals and recommendations to optimize cancer screening informed by a series of meetings conducted 2020-2021.

CAGPM Spotlights: Get to Know Our People

Over the past few months, we talked with some CAGPM team members to get to know them a little better — their roles in the center, what excites them about their work, and some words of advice.